Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).

Authors

Joyce O'Shaughnessy

Texas Oncology - Baylor Charles A. Sammons Cancer Center and The US Oncology Network, Dallas, TX

Joyce O'Shaughnessy , Martine J. Piccart-Gebhart , Lee Steven Schwartzberg , Javier Cortes , Nadia Harbeck , Seock-Ah Im , Hope S. Rugo , Michael Untch , Denise A. Yardley , Igor Bondarenko , Stephen Chan , Veronique Dieras , Luca Gianni , Mark D. Pegram , Stew Kroll , Joseph P. O'Connell , Jeffrey L. Vacirca , Thomas Wei , Kevin Tang , Andrew David Seidman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT03326674

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS1106)

DOI

10.1200/JCO.2018.36.15_suppl.TPS1106

Abstract #

TPS1106

Poster Bd #

184a

Abstract Disclosures

FEATURED

Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).

Authors

Joyce O'Shaughnessy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.

Poster

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

Poster

Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Poster

Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).